Compare Eli Lilly And Co (LLY) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Financial Select Sector SPDR Fund — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Financial Select Sector SPDR Fund trades at $54.73 (market cap $50.06B). The key difference: Eli Lilly And Co is far larger — about 20.8× Financial Select Sector SPDR Fund's market cap, and Eli Lilly And Co pays a 0.59% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| LLY | XLF | |
|---|---|---|
Market Cap | $1.04T | $50.06B |
Volume | 3,064,878 | 47,464,120 |
Sector | Health | — |
52-Week High | $1.28K | $58.55 |
52-Week Low | $799.57 | $47.80 |
Typical Hold Time | 93 Days | 104 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
XLF trades at $54.23, up 0.89% on the day, while technical indicators show a bearish bias with moving averages signaling caution. The ETF faces sector headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
Financial sector exposure through XLF offers potential upside from rising interest rates, though regulatory uncertainty and market underperformance present near-term risks. The ETF's focus on large-cap financial firms provides stability, but sector rotation trends and political volatility could impact medium-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
